Korro Bio (KRRO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KRRO SEC filings page.
Korro Bio, Inc. (KRRO) reported $2.4M in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Korro Bio remains development-stage: revenue increased, but research spending stayed large as cash losses persisted and equity shrank.
Revenue rose181.5% from FY2024 to FY2025, but R&D still increased3.0% . Operating cash flow was-$78.561M in FY2025 versus-$60.074M in FY2024, so the larger top line has not yet changed the cash-consuming operating model.
R&D rose
Capital expenditures fell
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Korro Bio, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Korro Bio, Inc. held $85.2M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $78.6M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Korro Bio, Inc. scores 37/100 among other emerging companies.
Korro Bio, Inc. had 14M shares outstanding at the end of fiscal year 2025, against 9M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Korro Bio, Inc. scores 25/100 among other emerging companies.
Korro Bio, Inc. spent $65.6M on research and development in fiscal year 2025, which was 51.1% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Korro Bio, Inc. scores 77/100 among other emerging companies.
Korro Bio, Inc. reported revenue of $6.4M in fiscal year 2025, against $2.3M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Korro Bio, Inc. scores 90/100 among other emerging companies.
Korro Bio, Inc.'s operations used $78.6M of cash in fiscal year 2025, against $60.1M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Korro Bio, Inc. scores 40/100 among other emerging companies.
Korro Bio, Inc.'s cash, cash equivalents and investments came to $85.2M at the end of fiscal year 2025, against $62.1M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Korro Bio, Inc. scores 68/100 among other emerging companies.
Korro Bio, Inc. scores -5.77, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $383.8M against total assets of $113.5M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Korro Bio, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.
Korro Bio, Inc. reported a net loss of $117.3M while operations used $78.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Korro Bio, Inc. generated $0 in revenue in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Korro Bio, Inc.'s EBITDA was -$19.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Korro Bio, Inc. reported a net loss of $18.9M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Korro Bio, Inc. recorded an outflow of $17.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Korro Bio, Inc. held $24.9M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Margins & Returns
Korro Bio, Inc.'s quarterly ROE was -18.3% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 4.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.9 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Korro Bio, Inc. invested $13.6M in research and development in Q2 2026. This represents a decrease of 32.5% from the same quarter a year earlier. Against the prior quarter it is up 4.9%.
Korro Bio, Inc. invested $37K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 73.6% from the same quarter a year earlier. Against the prior quarter it is up 76.2%.
Not reported for Q2 2026.
KRRO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0-100.0% | $0-100.0% | $1.3M | $1.1Mn/m | $1.5Mn/m | $2.5Mn/m | N/A | $0 |
| R&D Expenses | $13.6M-32.5% | $13.0M-34.4% | $11.9M | $13.8M-13.4% | $20.1M+17.5% | $19.7M+45.4% | N/A | $16.0M+14.0% |
| SG&A Expenses | $6.5M-10.6% | $7.5M-4.4% | $6.5M | $6.5M-11.2% | $7.3M+4.4% | $7.8M-0.6% | N/A | $7.3M+42.6% |
| Operating Income | -$20.1Mn/m | -$20.4Mn/m | -$50.4M | -$19.2Mn/m | -$27.2Mn/m | -$25.0Mn/m | N/A | -$23.3Mn/m |
| EBITDA | -$19.7Mn/m | -$20.1Mn/m | -$49.7M | -$18.0Mn/m | -$26.0Mn/m | -$23.8Mn/m | N/A | -$22.4Mn/m |
| Income Tax | $108K+10700.0% | $95Kn/m | $636K | $0n/m | $1K-96.7% | $0-100.0% | N/A | -$9Kn/m |
| Net Income | -$18.9Mn/m | -$19.6Mn/m | -$50.0M | -$18.1Mn/m | -$25.8Mn/m | -$23.4Mn/m | N/A | -$21.0Mn/m |
| EPS (Basic) | -$1.07 | -$1.69n/m | -$5.32n/m | -$1.92n/m | -$2.74n/m | -$2.49n/m | -$2.26 | -$2.26 |
| EPS (Diluted) | -$1.07 | -$1.69n/m | -$5.32n/m | -$1.92n/m | -$2.74n/m | -$2.49n/m | -$2.26 | -$2.26 |
| Diluted Shares (Avg) | 18M | 12M+23.6% | N/A | 9M+0.9% | 9M+4.5% | 9M+17.0% | N/A | 9M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
KRRO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $163.4M-9.4% | $183.6M-9.2% | $113.5M-49.8% | $161.6M-33.7% | $180.4M-27.7% | $202.2M+2.1% | $226.2M+2.1% | $243.5M+425.5% |
| Current Assets | $120.6M+17.5% | $120.2M-0.9% | $82.4M-37.4% | $98.2M-35.7% | $102.6M-37.3% | $121.2M-16.8% | $131.5M-23.9% | $152.8M+259.5% |
| Cash & Equivalents | $24.9M-25.9% | $61.7M-3.8% | $21.8M-60.8% | $24.2M-61.8% | $33.6M-63.1% | $64.1M-53.8% | $55.6M-66.5% | $63.2M+51.5% |
| Short-Term Investments | $90.1M+43.6% | $52.3M+2.9% | $53.3M-24.3% | $68.3M-7.4% | $62.8M-5.3% | $50.8Mn/m | $70.5Mn/m | $73.8Mn/m |
| Long-Term Investments | $22.9M-1.6% | $43.1M+79.2% | $10.0M-72.9% | $10.0M-68.8% | $23.3M-23.3% | $24.0Mn/m | $37.0Mn/m | $32.1Mn/m |
| Total Liabilities | $60.2M-7.8% | $64.0M+1.2% | $62.1M-5.7% | $62.5M-2.2% | $65.3M+26.8% | $63.3M+35.7% | $65.8M+27.2% | $63.9M-68.0% |
| Current Liabilities | $12.6M-26.5% | $14.8M+14.8% | $11.9M-20.2% | $14.6M+7.6% | $17.2M+39.3% | $12.9M+16.5% | $15.0M-23.2% | $13.6M+41.6% |
| Non-Current Liabilities | $47.6M-1.2% | $49.2M-2.3% | $50.1M-1.4% | $47.9M-4.8% | $48.1M+22.9% | $50.4M+41.6% | $50.9M+57.6% | $50.3M-73.5% |
| Total Equity | $103.2M-10.3% | $119.6M-13.9% | $51.4M-67.9% | $99.0M-44.9% | $115.1M-41.9% | $139.0M-8.2% | $160.4M-5.6% | $179.6Mn/m |
| Retained Earnings | -$422.4Mn/m | -$403.5Mn/m | -$383.8Mn/m | -$333.8Mn/m | -$315.7Mn/m | -$290.0Mn/m | -$266.6Mn/m | -$245.4Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
KRRO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$17.0Mn/m | -$16.1Mn/m | -$17.7Mn/m | -$17.2Mn/m | -$19.2Mn/m | -$24.5Mn/m | -$7.5Mn/m | -$16.1Mn/m |
| Depreciation & Amortization | $400K-66.7% | $380K-69.0% | $649K-48.2% | $1.2M+33.3% | $1.2M+71.4% | $1.2M+68.7% | $1.3M+27.2% | $900K+133.8% |
| Stock-Based Compensation | $2.7M+35.3% | $2.7M+55.1% | N/A | $1.8M+43.4% | $2.0M+106.6% | $1.8M+103.6% | N/A | $1.3M+215.1% |
| Capital Expenditures | $37K-73.6% | $21K-82.4% | $84K-94.2% | $175K-96.4% | $140K-97.7% | $119K-97.9% | $1.5M-12.3% | $4.9M+1882.9% |
| Free Cash Flow | -$17.0Mn/m | -$16.1Mn/m | -$17.8Mn/m | -$17.4Mn/m | -$19.4Mn/m | -$24.6Mn/m | -$8.9Mn/m | -$21.0Mn/m |
| Investing Cash Flow | -$17.9Mn/m | -$32.2M-198.3% | $14.9Mn/m | $7.6Mn/m | -$11.3Mn/m | $32.8Mn/m | -$2.8Mn/m | -$12.6M-1768.2% |
| Financing Cash Flow | -$2.9M-58440.0% | $88.2M+51186.0% | $380K-59.2% | $128K-82.4% | $5K-100.0% | $172K+23.7% | $932K-99.4% | $728Kn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
KRRO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | -3900.6% | -1764.9% | -1863.2% | -981.2% | N/A | N/A |
| Net Margin | N/A | N/A | -3873.2% | -1657.0% | -1765.1% | -917.1% | N/A | N/A |
| Return on Equity | -18.3%+4.1pp | -16.4%+0.4pp | -97.3% | -18.2%-6.6pp | -22.4%-11.4pp | -16.8%-3.9pp | N/A | -11.7% |
| Return on Assets | -11.6%+2.7pp | -10.7%+0.9pp | -44.1% | -11.2%-2.6pp | -14.3%-5.5pp | -11.6%-1.7pp | N/A | -8.6%+31.3pp |
| Current Ratio | 9.55+3.6x | 8.13-1.3x | 6.90-1.9x | 6.71-4.5x | 5.98-7.3x | 9.41-3.8x | 8.79-0.1x | 11.23+6.8x |
| Liabilities-to-Equity | 0.580.0x | 0.53+0.1x | 1.21+0.8x | 0.63+0.3x | 0.57+0.3x | 0.46+0.1x | 0.41+0.1x | 0.36 |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.01 | 0.010.0x | 0.010.0x | 0.010.0x | N/A | 0.00 |
| FCF Margin | N/A | N/A | -1376.6% | -1592.1% | -1326.6% | -963.6% | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Korro Bio, Inc. KRRO | FY2025 | $6.4M | -$117.3M | N/A | $177.0M | 56/100 |
| Larimar Therapeutics, Inc. LRMR | FY2025 | N/A | -$165.7M | N/A | $232.7M | — |
| 4D Molecular Therapeutics, Inc. FDMT | FY2025 | $85.2M | -$140.1M | N/A | $609.3M | 72/100 |
| enGene Therapeutics Inc. ENGN | FY2025 | N/A | -$117.3M | N/A | $105.9M | — |
| Benitec Biopharma Inc. BNTC | FY2026 | N/A | -$45.5M | N/A | $299.7M | — |
| Immuneering Corporation IMRX | FY2025 | N/A | -$56.0M | N/A | $240.0M | — |
Where Korro Bio, Inc. Ranks
Frequently Asked Questions
What is Korro Bio, Inc.'s annual revenue?
Korro Bio, Inc. (KRRO) reported $6.4M in total revenue for fiscal year 2025. This represents a 181.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Korro Bio, Inc.'s revenue growing?
Korro Bio, Inc. (KRRO) revenue grew by 181.5% year-over-year, from $2.3M to $6.4M in fiscal year 2025.
Is Korro Bio, Inc. profitable?
No, Korro Bio, Inc. (KRRO) reported a net loss of $106.6M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $117.3M.
What is Korro Bio, Inc.'s EBITDA?
Korro Bio, Inc. (KRRO) had EBITDA of -$117.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Korro Bio, Inc.'s return on equity (ROE)?
Korro Bio, Inc. (KRRO) has a return on equity of -228.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Korro Bio, Inc.'s free cash flow?
Korro Bio, Inc. (KRRO) recorded an outflow of $79.1M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Korro Bio, Inc.'s operating cash flow?
Korro Bio, Inc. (KRRO) recorded an outflow of $78.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Korro Bio, Inc.'s total assets?
Korro Bio, Inc. (KRRO) had $113.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Korro Bio, Inc.'s capital expenditures?
Korro Bio, Inc. (KRRO) invested $518K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Korro Bio, Inc. spend on research and development?
Korro Bio, Inc. (KRRO) invested $65.6M in research and development during fiscal year 2025.
What is Korro Bio, Inc.'s current ratio?
Korro Bio, Inc. (KRRO) had a current ratio of 6.90 as of fiscal year 2025, which is generally considered healthy.
What is Korro Bio, Inc.'s liabilities-to-equity ratio?
Korro Bio, Inc. (KRRO) had a liabilities-to-equity ratio of 1.21 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Korro Bio, Inc.'s return on assets (ROA)?
Korro Bio, Inc. (KRRO) had a return on assets of -103.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Korro Bio, Inc.'s P/E ratio?
Korro Bio, Inc. (KRRO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $177.0M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Korro Bio, Inc.'s price-to-sales ratio?
Korro Bio, Inc. (KRRO) trades at 74.3x sales, its market capitalization divided by $2.4M revenue, trailing 12 months to June 30, 2026. The market capitalization is $177.0M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Korro Bio, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Korro Bio, Inc. (KRRO) held $85.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $78.6M over that year. Dividing the one by the other, the reported balance equals about 13 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Korro Bio, Inc.'s Altman Z-Score?
Korro Bio, Inc. (KRRO) has an Altman Z-Score of -5.77, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Korro Bio, Inc.'s Piotroski F-Score?
Korro Bio, Inc. (KRRO) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Korro Bio, Inc.'s earnings high quality?
Korro Bio, Inc. (KRRO) reported a net loss of $117.3M while operations used $78.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Korro Bio, Inc.?
Korro Bio, Inc. (KRRO) scores 56 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.